Mupirocin
Methicillin-resistant Staphylococcus Aureus
University of North Carolina, Chapel HillSmall moleculePhase 2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Methicillin-resistant Staphylococcus Aureus cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
SULFAMETHOXAZOLE University of North Carolina, Chapel Hill | Phase 4 | BBB |
Trimethoprim University of North Carolina, Chapel Hill | Phase 4 | BBB |
RIFALDAZINE Johns Hopkins University | Phase 4 | BB |
Vancomycin Savara Inc. | Phase 3 | BB |
Cephalexin Mayo Clinic | Phase 4 | BB |
View all 9 →
Same molecule, other indications
Mupirocin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →